Quarterly ResultMay 7, 2026, 04:20 PM
Oncology Institute Q1 Net Loss $(2.49)M; Revenue +41.2% to $147.4M
AI Summary
The Oncology Institute, Inc. reported a significant improvement in its first-quarter 2026 financial results, with net loss narrowing to $(2.49) million from $(19.59) million in the prior year. Total operating revenue increased by 41.2% to $147.44 million, primarily driven by a substantial 77.6% growth in Specialty Pharmacy revenue. Despite an accumulated deficit, the company believes it has sufficient liquidity for the next year, while still facing vendor concentration risks.
Key Highlights
- Net loss improved to $(2.49)M in Q1 2026 from $(19.59)M in Q1 2025.
- Total operating revenue increased 41.2% to $147.44M from $104.41M year-over-year.
- Specialty Pharmacy revenue surged 77.6% to $87.54M from $49.29M.
- Patient services revenue grew 11.3% to $59.09M from $53.07M.
- Net loss per share improved to $(0.02) from $(0.21) in the prior year.
- Net cash used in operating activities improved to $(2.22)M from $(4.99)M.
- Cash and cash equivalents stood at $30.28M as of March 31, 2026.
- Vendor A accounted for 93% of direct costs and 72% of gross payables.